Related Experiment Video
Updated: Dec 16, 2025
Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
Generation and immunogenicity of virus-like particles based on mink enteritis virus capsid protein VP2 expressed in
Hongchao Wu1, Hongli Jin2, Lingxiao Wang1
1National Research Center for Veterinary Medicine, No. 3 Cuiwei Road, High-Tech District, Luoyang, 471003, Henan, China.
Abstract:
Mink enteritis virus (MEV) is a parvovirus that causes acute enteritis in mink. The capsid protein VP2 of MEV is a major immunogenicity that is important for disease prevention. In this study, this protein was expressed in Spodoptera frugiperda 9 cells using a recombinant baculovirus system and was observed to self-assemble into virus-like particles (VLPs) with a high hemagglutination (HA) titer (1:216). A single-dose injection of VLPs (HA titer, 1:256) resulted in complete protection of mink against virulent MEV challenge for at least 180 days. These data suggest that these MEV VLPs could be used as a vaccine for the prevention of viral enteritis in mink.
Insights
Mink enteritis virus (MEV) capsid protein VP2 was used to create virus-like particles (VLPs). These MEV VLPs provided complete protection against virulent MEV infection in mink for over six months.
Area of Science:
- Veterinary Virology
- Immunology
- Molecular Biology
Background:
- Mink enteritis virus (MEV) causes severe gastrointestinal illness in mink.
- The VP2 capsid protein of MEV is a key target for immune responses and vaccine development.
Purpose of the Study:
- To express and characterize the MEV VP2 protein.
- To evaluate the immunogenicity and protective efficacy of self-assembled MEV virus-like particles (VLPs) in mink.
Main Methods:
- Recombinant baculovirus expression system used to produce MEV VP2 in Spodoptera frugiperda 9 cells.
- Characterization of self-assembled VLPs, including hemagglutination (HA) titer determination.
- Vaccination of mink with a single dose of MEV VLPs followed by challenge with virulent MEV.
Main Results:
- MEV VP2 self-assembled into VLPs with a high hemagglutination titer (1:2^16).
- A single VLP injection (HA titer, 1:256) conferred complete protection against virulent MEV challenge.
- Protection was sustained for at least 180 days post-vaccination.
Conclusions:
- MEV VLPs are highly immunogenic and capable of inducing long-lasting protective immunity.
- MEV VLPs represent a promising candidate for a novel vaccine against mink enteritis.
More Related Videos
08:10Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
Published on: January 15, 2020
08:40Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
Published on: March 1, 2019